Skip to main content
Top
Published in: European Journal of Nutrition 2/2013

01-03-2013 | Original Contribution

Combined arginine and glutamine decrease release of de novo synthesized leukotrienes and expression of proinflammatory cytokines in activated human intestinal mast cells

Authors: Sandra Lechowski, Katharina Feilhauer, Ludger Staib, Moïse Coëffier, Stephan C. Bischoff, Axel Lorentz

Published in: European Journal of Nutrition | Issue 2/2013

Login to get access

Abstract

Purpose
Glutamine and arginine modulate inflammatory responses of epithelial cells and monocytes. Here, we studied the response of human mast cells to pharmacological doses of arginine and glutamine.

Methods

Mast cells isolated from intestinal tissue were incubated with physiological doses of arginine (0.1 mmol/L) and glutamine (0.6 mmol/L) or with pharmacological doses of arginine (2 mmol/L) and glutamine (10 mmol/L) for 18 h. Following stimulation by IgE receptor crosslinking mast cell mediators were measured by enzymatic assay, ELISA, multiplex bead immunoassay, or real-time RT-PCR, and activation of intracellular signaling molecules was determined using proteome profiler array or immunoblotting.

Results

We found that the combined challenge of mast cells with pharmacological doses of arginine and glutamine caused a decrease in induced release of de novo synthesized leukotriene C4 but not of pre-stored β-hexosaminidase. Moreover, we found reduced expression of chemokines monocyte chemoattractant protein-1 (CCL2), macrophage inflammatory protein-1β (CCL4), IL-8 (CXCL8), and TNF in response to high doses of both amino acids. The anti-inflammatory effects of arginine and glutamine were associated with decreased activation levels of signaling molecules known to be involved in mast cell cytokine expression such as MAPK family members extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38, and the protein kinase B (Akt).

Conclusion

Arginine and glutamine attenuate IgE-dependent human mast cell activation by decreasing lipid mediator release and expression of proinflammatory cytokines.
Literature
1.
go back to reference Nieves C Jr, Langkamp-Henken B (2002) Arginine and immunity: a unique perspective. Biomed Pharmacother 56:471–482CrossRef Nieves C Jr, Langkamp-Henken B (2002) Arginine and immunity: a unique perspective. Biomed Pharmacother 56:471–482CrossRef
2.
go back to reference Powell-Tuck J (2007) Nutritional interventions in critical illness. Proc Nutr Soc 66:16–24CrossRef Powell-Tuck J (2007) Nutritional interventions in critical illness. Proc Nutr Soc 66:16–24CrossRef
3.
go back to reference Lecleire S, Hassan A, Marion-Letellier R, Antonietti M, Savoye G, Bole-Feysot C, Lerebours E, Ducrotte P, Dechelotte P, Coeffier M (2008) Combined glutamine and arginine decrease proinflammatory cytokine production by biopsies from Crohn’s patients in association with changes in nuclear factor-kappaB and p38 mitogen-activated protein kinase pathways. J Nutr 138:2481–2486CrossRef Lecleire S, Hassan A, Marion-Letellier R, Antonietti M, Savoye G, Bole-Feysot C, Lerebours E, Ducrotte P, Dechelotte P, Coeffier M (2008) Combined glutamine and arginine decrease proinflammatory cytokine production by biopsies from Crohn’s patients in association with changes in nuclear factor-kappaB and p38 mitogen-activated protein kinase pathways. J Nutr 138:2481–2486CrossRef
4.
go back to reference Kolios G, Valatas V, Ward SG (2004) Nitric oxide in inflammatory bowel disease, a universal messenger in an unsolved puzzle. Immunology 113:427–437CrossRef Kolios G, Valatas V, Ward SG (2004) Nitric oxide in inflammatory bowel disease, a universal messenger in an unsolved puzzle. Immunology 113:427–437CrossRef
5.
go back to reference Suchner U, Heyland DK, Peter K (2002) Immune-modulatory actions of arginine in the critically ill. Br J Nutr 87(Suppl 1):121–132 Suchner U, Heyland DK, Peter K (2002) Immune-modulatory actions of arginine in the critically ill. Br J Nutr 87(Suppl 1):121–132
6.
go back to reference Coeffier M, Marion-Letellier R, Dechelotte P (2010) Potential for amino acids supplementation during inflammatory bowel diseases. Inflamm Bowel Dis 16:518–524CrossRef Coeffier M, Marion-Letellier R, Dechelotte P (2010) Potential for amino acids supplementation during inflammatory bowel diseases. Inflamm Bowel Dis 16:518–524CrossRef
7.
go back to reference Chang WK, Yang KD, Chuang H, Jan JT, Shaio MF (2002) Glutamine protects activated human T cells from apoptosis by up-regulating glutathione and Bcl-2 levels. Clin Immunol 104:151–160CrossRef Chang WK, Yang KD, Chuang H, Jan JT, Shaio MF (2002) Glutamine protects activated human T cells from apoptosis by up-regulating glutathione and Bcl-2 levels. Clin Immunol 104:151–160CrossRef
8.
go back to reference Wischmeyer PE, Riehm J, Singleton KD, Ren H, Musch MW, Kahana M, Chang EB (2003) Glutamine attenuates tumor necrosis factor-alpha release and enhances heat shock protein 72 in human peripheral blood mononuclear cells. Nutrition 19:1–6CrossRef Wischmeyer PE, Riehm J, Singleton KD, Ren H, Musch MW, Kahana M, Chang EB (2003) Glutamine attenuates tumor necrosis factor-alpha release and enhances heat shock protein 72 in human peripheral blood mononuclear cells. Nutrition 19:1–6CrossRef
9.
go back to reference Fukatsu K, Kudsk KA, Zarzaur BL, Wu Y, Hanna MK, DeWitt RC (2001) TPN decreases IL-4 and IL-10 mRNA expression in lipopolysaccharide stimulated intestinal lamina propria cells but glutamine supplementation preserves the expression. Shock 15:318–322CrossRef Fukatsu K, Kudsk KA, Zarzaur BL, Wu Y, Hanna MK, DeWitt RC (2001) TPN decreases IL-4 and IL-10 mRNA expression in lipopolysaccharide stimulated intestinal lamina propria cells but glutamine supplementation preserves the expression. Shock 15:318–322CrossRef
10.
go back to reference Horio Y, Osawa S, Takagaki K, Hishida A, Furuta T, Ikuma M (2008) Glutamine supplementation increases Th1-cytokine responses in murine intestinal intraepithelial lymphocytes. Cytokine 44:92–95CrossRef Horio Y, Osawa S, Takagaki K, Hishida A, Furuta T, Ikuma M (2008) Glutamine supplementation increases Th1-cytokine responses in murine intestinal intraepithelial lymphocytes. Cytokine 44:92–95CrossRef
11.
go back to reference Boelens PG, Houdijk AP, Fonk JC, Nijveldt RJ, Ferwerda CC, Von Blomberg-Van Der Flier BM, Thijs LG, Haarman HJ, Puyana JC, Van Leeuwen PA (2002) Glutamine-enriched enteral nutrition increases HLA-DR expression on monocytes of trauma patients. J Nutr 132:2580–2586 Boelens PG, Houdijk AP, Fonk JC, Nijveldt RJ, Ferwerda CC, Von Blomberg-Van Der Flier BM, Thijs LG, Haarman HJ, Puyana JC, Van Leeuwen PA (2002) Glutamine-enriched enteral nutrition increases HLA-DR expression on monocytes of trauma patients. J Nutr 132:2580–2586
12.
go back to reference Wells SM, Kew S, Yaqoob P, Wallace FA, Calder PC (1999) Dietary glutamine enhances cytokine production by murine macrophages. Nutrition 15:881–884CrossRef Wells SM, Kew S, Yaqoob P, Wallace FA, Calder PC (1999) Dietary glutamine enhances cytokine production by murine macrophages. Nutrition 15:881–884CrossRef
13.
go back to reference Kretzmann NA, Fillmann H, Mauriz JL, Marroni CA, Marroni N, Gonzalez-Gallego J, Tunon MJ (2008) Effects of glutamine on proinflammatory gene expression and activation of nuclear factor kappa B and signal transducers and activators of transcription in TNBS-induced colitis. Inflamm Bowel Dis 14:1504–1513CrossRef Kretzmann NA, Fillmann H, Mauriz JL, Marroni CA, Marroni N, Gonzalez-Gallego J, Tunon MJ (2008) Effects of glutamine on proinflammatory gene expression and activation of nuclear factor kappa B and signal transducers and activators of transcription in TNBS-induced colitis. Inflamm Bowel Dis 14:1504–1513CrossRef
14.
go back to reference Coeffier M, Marion R, Leplingard A, Lerebours E, Ducrotte P, Dechelotte P (2002) Glutamine decreases interleukin-8 and interleukin-6 but not nitric oxide and prostaglandins e(2) production by human gut in vitro. Cytokine 18:92–97CrossRef Coeffier M, Marion R, Leplingard A, Lerebours E, Ducrotte P, Dechelotte P (2002) Glutamine decreases interleukin-8 and interleukin-6 but not nitric oxide and prostaglandins e(2) production by human gut in vitro. Cytokine 18:92–97CrossRef
15.
go back to reference Coeffier M, Marion R, Ducrotte P, Dechelotte P (2003) Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut. Clin Nutr 22:407–413CrossRef Coeffier M, Marion R, Ducrotte P, Dechelotte P (2003) Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut. Clin Nutr 22:407–413CrossRef
16.
go back to reference Galli SJ, Grimbaldeston M, Tsai M (2008) Immunomodulatory mast cells, negative, as well as positive, regulators of immunity. Nat Rev Immunol 8:478–486CrossRef Galli SJ, Grimbaldeston M, Tsai M (2008) Immunomodulatory mast cells, negative, as well as positive, regulators of immunity. Nat Rev Immunol 8:478–486CrossRef
17.
go back to reference Bischoff SC (2009) Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol 31:185–205CrossRef Bischoff SC (2009) Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol 31:185–205CrossRef
18.
go back to reference Rijnierse A, Nijkamp FP, Kraneveld AD (2007) Mast cells and nerves tickle in the tummy, implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther 116:207–235CrossRef Rijnierse A, Nijkamp FP, Kraneveld AD (2007) Mast cells and nerves tickle in the tummy, implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther 116:207–235CrossRef
19.
go back to reference He SH (2004) Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 10:309–318 He SH (2004) Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 10:309–318
20.
go back to reference Lilja I, Gustafson-Svard C, Franzen L, Sjodahl R (2000) Tumor necrosis factor-alpha in ileal mast cells in patients with Crohn’s disease. Digestion 61:68–76CrossRef Lilja I, Gustafson-Svard C, Franzen L, Sjodahl R (2000) Tumor necrosis factor-alpha in ileal mast cells in patients with Crohn’s disease. Digestion 61:68–76CrossRef
21.
go back to reference Sellge G, Bischoff SC (2006) Isolation, culture, and characterization of intestinal mast cells. Methods Mol Biol 315:123–138 Sellge G, Bischoff SC (2006) Isolation, culture, and characterization of intestinal mast cells. Methods Mol Biol 315:123–138
22.
go back to reference Bischoff SC, Sellge G, Lorentz A, Sebald W, Raab R, Manns MP (1999) IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci U S A 96:8080–8085CrossRef Bischoff SC, Sellge G, Lorentz A, Sebald W, Raab R, Manns MP (1999) IL-4 enhances proliferation and mediator release in mature human mast cells. Proc Natl Acad Sci U S A 96:8080–8085CrossRef
23.
go back to reference Lorentz A, Schwengberg S, Sellge G, Manns MP, Bischoff SC (2000) Human intestinal mast cells are capable of producing different cytokine profiles, role of IgE receptor cross-linking and IL-4. J Immunol 164:43–48 Lorentz A, Schwengberg S, Sellge G, Manns MP, Bischoff SC (2000) Human intestinal mast cells are capable of producing different cytokine profiles, role of IgE receptor cross-linking and IL-4. J Immunol 164:43–48
24.
go back to reference Thienemann F, Henz BM, Babina M (2004) Regulation of mast cell characteristics by cytokines, divergent effects of interleukin-4 on immature mast cell lines versus mature human skin mast cells. Arch Dermatol Res 296:134–138CrossRef Thienemann F, Henz BM, Babina M (2004) Regulation of mast cell characteristics by cytokines, divergent effects of interleukin-4 on immature mast cell lines versus mature human skin mast cells. Arch Dermatol Res 296:134–138CrossRef
25.
go back to reference Marion R, Coëffier MM, Gargala G, Ducrotté P, Déchelotte PP (2004) Glutamine and CXC chemokines IL-8, Mig, IP-10 and I-TAC in human intestinal epithelial cells. Clin Nutr 23:579–585CrossRef Marion R, Coëffier MM, Gargala G, Ducrotté P, Déchelotte PP (2004) Glutamine and CXC chemokines IL-8, Mig, IP-10 and I-TAC in human intestinal epithelial cells. Clin Nutr 23:579–585CrossRef
26.
go back to reference Marion R, Coeffier M, Lemoulan S, Gargala G, Ducrotte P, Dechelotte P (2005) l-Arginine modulates CXC chemokines in the human intestinal epithelial cell line HCT-8 by the NO pathway. Biochimie 87:1048–1055CrossRef Marion R, Coeffier M, Lemoulan S, Gargala G, Ducrotte P, Dechelotte P (2005) l-Arginine modulates CXC chemokines in the human intestinal epithelial cell line HCT-8 by the NO pathway. Biochimie 87:1048–1055CrossRef
27.
go back to reference Lecleire S, Coeffier M, Leblond J, Hubert A, Lemoulan S, Petit A, Ducrotte P, Dechelotte P, Marion R (2005) Modulation of nitric oxide and cytokines production by l-arginine in human gut mucosa. Clin Nutr 24:353–359CrossRef Lecleire S, Coeffier M, Leblond J, Hubert A, Lemoulan S, Petit A, Ducrotte P, Dechelotte P, Marion R (2005) Modulation of nitric oxide and cytokines production by l-arginine in human gut mucosa. Clin Nutr 24:353–359CrossRef
28.
go back to reference Schwartz LB, Austen KF, Wasserman SI (1979) Immunologic release of beta-hexosaminidase and beta-glucuronidase from purified rat serosal mast cells. J Immunol 123:1445–1450 Schwartz LB, Austen KF, Wasserman SI (1979) Immunologic release of beta-hexosaminidase and beta-glucuronidase from purified rat serosal mast cells. J Immunol 123:1445–1450
29.
go back to reference Feuser K, Feilhauer K, Staib L, Bischoff SC, Lorentz A (2011) Akt cross-links IL-4 priming, stem cell factor signaling, and IgE-dependent activation in mature human mast cells. Mol Immunol 48:546–552CrossRef Feuser K, Feilhauer K, Staib L, Bischoff SC, Lorentz A (2011) Akt cross-links IL-4 priming, stem cell factor signaling, and IgE-dependent activation in mature human mast cells. Mol Immunol 48:546–552CrossRef
30.
go back to reference Lorentz A, Wilke M, Sellge G, Worthmann H, Klempnauer J, Manns MP, Bischoff SC (2005) IL-4-induced priming of human intestinal mast cells for enhanced survival and Th2 cytokine generation is reversible and associated with increased activity of ERK1/2 and c-Fos. J Immunol 174:6751–6756 Lorentz A, Wilke M, Sellge G, Worthmann H, Klempnauer J, Manns MP, Bischoff SC (2005) IL-4-induced priming of human intestinal mast cells for enhanced survival and Th2 cytokine generation is reversible and associated with increased activity of ERK1/2 and c-Fos. J Immunol 174:6751–6756
31.
go back to reference Hubert-Buron A, Leblond J, Jacquot A, Ducrotte P, Dechelotte P, Coeffier M (2006) Glutamine pretreatment reduces IL-8 production in human intestinal epithelial cells by limiting IkappaBalpha ubiquitination. J Nutr 136:1461–1465 Hubert-Buron A, Leblond J, Jacquot A, Ducrotte P, Dechelotte P, Coeffier M (2006) Glutamine pretreatment reduces IL-8 production in human intestinal epithelial cells by limiting IkappaBalpha ubiquitination. J Nutr 136:1461–1465
32.
go back to reference Mañé J, Fernández-Bañares F, Ojanguren I, Castellá E, Bertrán X, Bartolí R, Alvarez M, Gassull MA (2001) Effect of l-arginine on the course of experimental colitis. Clin Nutr 20:415–422CrossRef Mañé J, Fernández-Bañares F, Ojanguren I, Castellá E, Bertrán X, Bartolí R, Alvarez M, Gassull MA (2001) Effect of l-arginine on the course of experimental colitis. Clin Nutr 20:415–422CrossRef
33.
go back to reference Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S (2002) p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 168:5342–5351 Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S (2002) p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 168:5342–5351
34.
go back to reference Lockyer HM, Tran E, Nelson BH (2007) STAT5 is essential for Akt/p70S6 kinase activity during IL-2-induced lymphocyte proliferation. J Immunol 179:5301–5308 Lockyer HM, Tran E, Nelson BH (2007) STAT5 is essential for Akt/p70S6 kinase activity during IL-2-induced lymphocyte proliferation. J Immunol 179:5301–5308
35.
go back to reference Ruiz PA, Haller D (2006) Functional diversity of flavonoids in the inhibition of the proinflammatory NF-kappaB, IRF, and Akt signaling pathways in murine intestinal epithelial cells. J Nutr 136:664–671 Ruiz PA, Haller D (2006) Functional diversity of flavonoids in the inhibition of the proinflammatory NF-kappaB, IRF, and Akt signaling pathways in murine intestinal epithelial cells. J Nutr 136:664–671
36.
go back to reference Giris M, Erbil Y, Dogru-Abbasoglu S, Yanik BT, Alis H, Olgac V, Toker GA (2007) The effect of heme oxygenase-1 induction by glutamine on TNBS-induced colitis. Int J Colorectal Dis 22:591–599CrossRef Giris M, Erbil Y, Dogru-Abbasoglu S, Yanik BT, Alis H, Olgac V, Toker GA (2007) The effect of heme oxygenase-1 induction by glutamine on TNBS-induced colitis. Int J Colorectal Dis 22:591–599CrossRef
37.
go back to reference Coskun M, Olsen J, Seidelin JB, Nielsen OH (2011) MAP kinases in inflammatory bowel disease. Clin Chim Acta 412:513–520CrossRef Coskun M, Olsen J, Seidelin JB, Nielsen OH (2011) MAP kinases in inflammatory bowel disease. Clin Chim Acta 412:513–520CrossRef
38.
go back to reference Neurath MF, Fuss I, Schurmann G et al (1998) Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci 859:149–159CrossRef Neurath MF, Fuss I, Schurmann G et al (1998) Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann N Y Acad Sci 859:149–159CrossRef
39.
go back to reference Schreiber S, Rosenstiel P, Hampe J, Nikolaus S, Groessner B, Schottelius A, Kuhbacher T, Hamling J, Folsch UR, Seegert D (2002) Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 51:379–385CrossRef Schreiber S, Rosenstiel P, Hampe J, Nikolaus S, Groessner B, Schottelius A, Kuhbacher T, Hamling J, Folsch UR, Seegert D (2002) Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 51:379–385CrossRef
40.
go back to reference Mudter J, Neurath MF (2007) IL-6 signaling in inflammatory bowel disease, pathophysiological role and clinical relevance. Inflamm Bowel Dis 13:1016–1023CrossRef Mudter J, Neurath MF (2007) IL-6 signaling in inflammatory bowel disease, pathophysiological role and clinical relevance. Inflamm Bowel Dis 13:1016–1023CrossRef
41.
go back to reference Levy DE, Darnell JE Jr (2002) Stats, transcriptional control and biological impact. Nat Rev Mol Cell Biol 3:651–662CrossRef Levy DE, Darnell JE Jr (2002) Stats, transcriptional control and biological impact. Nat Rev Mol Cell Biol 3:651–662CrossRef
42.
go back to reference Koon HW, Zhao D, Zhan Y, Rhee SH, Moyer MP, Pothoulakis C (2006) Substance P stimulates cyclooxygenase-2 and prostaglandin E2 expression through JAK-STAT activation in human colonic epithelial cells. J Immunol 176:5050–5059 Koon HW, Zhao D, Zhan Y, Rhee SH, Moyer MP, Pothoulakis C (2006) Substance P stimulates cyclooxygenase-2 and prostaglandin E2 expression through JAK-STAT activation in human colonic epithelial cells. J Immunol 176:5050–5059
Metadata
Title
Combined arginine and glutamine decrease release of de novo synthesized leukotrienes and expression of proinflammatory cytokines in activated human intestinal mast cells
Authors
Sandra Lechowski
Katharina Feilhauer
Ludger Staib
Moïse Coëffier
Stephan C. Bischoff
Axel Lorentz
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
European Journal of Nutrition / Issue 2/2013
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-012-0353-1

Other articles of this Issue 2/2013

European Journal of Nutrition 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.